News | January 25, 2022
USFDA rejects Merck’s gefapixant; gain approval in Japan
Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant
Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant
The tablet donations provided for the treatment of more than 600 million schoolchildren in affected countries in sub-Saharan Africa since 2007
The company has been manufacturing masks since the Covid-19 outbreak in 2020
The collaboration with Sanofi signifies a considerable investment in the UK’s Life Sciences sector and, along with other future strategic partners, has the potential to increase the pipeline of potential treatment options for a wide range of common and other life-threatening diseases
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
Madhavbaug has a pan-India presence with a vast network of 272 clinics and two hospitals
Al-Futtaim will utilize TytoCare's TytoPro system in outpatient clinics around Dubai, providing patients with enhanced care and better access to specialists
The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US
Previously, the use of the drug was limited to patients requiring hospitalization
UCB plans to submit regulatory applications in Q3 2022
Subscribe To Our Newsletter & Stay Updated
